April 04, 2026 03:44 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
AAP drops Raghav Chadha from key parliamentary role, sparks buzz over internal rift | Amit Shah to camp in West Bengal for 15 days during Assembly polls; predicts Mamata’s defeat in state and Bhabanipur | 'BJP plotting President’s Rule, don’t fall in the trap': Mamata Banerjee on Malda unrest, urges peace | 'Most polarised state': CJI Kant raps Bengal govt over 9-hour hostage of judicial officers | Bengal SIR protest: Judge pleads for help amid mob attack after 9-hour hostage ordeal | Bengal SIR progress: 47 lakh of 60 lakh adjudicated cases disposed of, Supreme Court informed | Amit Shah to join Suvendu Adhikari on Bhabanipur nomination day; BJP plans mega roadshow | Fuel prices rise: Premium petrol, diesel hiked amid oil price surge | Commercial LPG up Rs 195.50 as global oil prices rise; domestic rates unchanged | Layoff alert: Oracle cuts 30,000 jobs globally, 12,000 hit in India
Coronavirus Vaccine

Adar Poonawalla thanks PM Modi for decisive 'policy changes and swift financial aid' amid vaccine shortage

| @indiablooms | Apr 21, 2021, at 07:18 am

Mumbai/IBNS: Serum Institute of India (SII) CEO Adar Poonawalla has lauded the Centre's policy change in vaccination, bringing all above 18 under the mass drive and extending financial support to the vaccine manufacturers.

SII which is manufacturing Covishied, developed by Oxford University and Swedish drug giant AstraZeneca, in India has been given Rs 3,000 crore as 100 per cent advance till July, reported NDTV citing senior sources in the Finance Ministry.

A similar advance of Rs 1,500 crore has been given to Hyderabad-based Bharat Biotech, the producer of indegenous Covaxin, the report added.

"This will ensure that the two companies get necessary funding to continue and scale up production," the sources said, the report added.

Earlier, Adar Poonawalla had appealed to the Centre for funds to scale up manufacturing amid high demand of the vaccine within and outside India.

Both Bharat Biotech and SII were facing shortage of funds "to scale up production, purchase raw materials, pay staff, and make and distribute enough doses of the vaccines", stated the report.

Poonawall, on Tuesday, tweeted in appreciation of the Centre's move.

The states can now buy coronavirus vaccine doses directly from manufacturers in the "liberalised and accelerated Phase 3 strategy of COVID-19 vaccination".

.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.